Prospective validation of tumor folate receptor expression density with the association of pafolacianine fluorescence during intraoperative molecular imaging–guided lung cancer resections

Azari, Feredun; Zhang, Kevin; Kennedy, Gregory T.; Bou‐Samra, Patrick; Chang, Ashley; Nadeem, Bilal; Galandarova, Aysuna; Ibrahimli, Arturan; Karimov, Ziya; Din, Azra; Kucharczuk, John C.; Jarrar, Doraid; Pechet, Taine T.; Delikatny, Edward J.; Singhal, Sunil

doi:10.1007/s00259-023-06141-3

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression rate of the folate receptor is 74% in lung adenocarcinoma, while it is only 13% in lung squamous cell carcinoma . In clinical experiments of OTL38, patients with lung adenocarcinoma had a tumor-to-background ratio of 3.11 ± 0.31 compared to squamous cell carcinoma (1.89 ± 0.29). In contrast, EGFR expression in lung squamous cell carcinoma is 51.2%. , Based on this, the EGFR target may have better applicability in the field of lung cancer, as it is more suitable for lung squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Application of Epithelial Growth Factor Receptor-Targeted Magnetic Resonance Imaging and Near-Infrared II Dual-Modal Probe in Lung Cancer Diagnosis and Surgical Resection

Li,

Zhou

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

There has been an increase in the use of molecular probe diagnostic techniques for lung cancer, and magnetic resonance imaging (MRI) offers specific advantages for diagnosing pulmonary carcinoma. Furthermore, advancements in near-infrared II (NIR-II) fluorescence have provided a new method for precise intraoperative tumor resection. However, few probes combine preoperative diagnosis with intraoperative imaging. This study aims to fill this research void by employing a dual-modal probe that targets the epidermal growth factor receptor for MR and NIR-II imaging, enabling the preoperative diagnosis of lung cancer using MRI and precise intraoperative tumor localization using NIR-II with a single probe. The imaging effects and targeting ability of the probe were confirmed in cell lines, mouse models, and clinical samples. The MR signal decreased within 24 h in the patient-derived xenograft mouse model. The average signal-tobackground ratio of NIR-II reached 3.98 ± 0.27. The clinical sample also showed a decrease in the T2 signal using MRI, and the NIR-II optical signal-to-background ratio was 3.29. It is expected that this probe can improve the diagnostic rate of lung cancer using MRI and enable precise intraoperative tumor resection using NIR-II.

show abstract